Barbara Davis Center investigators are researching new treatments and prevention strategies for better outcomes for patients with type 1 diabetes. We have strong collaborators at Children’s Hospital of Colorado, Departments of the School of Medicine, Colorado School of Public Health and across the world through multi-center studies and trials including NIH funded clinical studies: TEDDY, DAISY, CACTI, TrialNet, ITN, and the Artificial Pancreas Project. Additional studies (ADA, JDRF, industry-sponsored, and T1D Exchange funded through the Helmsley Foundation) offer opportunities for discovery and mentored research.

The Barbara Davis Center has played a critical role in trials to provide new therapies to our patients. BDC investigators lead many industry sponsored and investigator initiated clinical trials to find ways to improve the lives of people with type 1 diabetes. These include studies involving new long and short acting insulins and other novel formulations of insulins that have changed the way insulin is delivered to offer more choices for patients to manage their diabetes. The Barbara Davis Center has also been involved in studies of non insulin therapies for glucose management in type 1 diabetes such as DPP-IV inhibitors, bile-acid sequestrants and SGLT1 and/or 2 inhibitors (all approved for type 2 diabetes management). Through excellence in research, patient care and education, our efforts will not cease until prevention and durable cure are widely available.

  • New treatments and specialized centers of excellence will improve outcomes and reduce acute and long-term complications from diabetes.

BDC researchers continue to lead the way in discoveries advancing the science of type 1 diabetes. Goals that will transform the disease as we know it include:

  • Understanding the role of the insulin-producing beta cell in type 1 diabetes (T1D) to develop therapies to prevent autoimmune-mediated destruction
  • Identifying biomarkers of pre-diabetic autoimmunity
  • Developing immunomodulation therapy (NEJM, 2019) to control or reverse pre-diabetic autoimmunity.
  • Finding the environmental triggers of autoimmunity that cause T1D.
  • Harnessing stem cell technology to provide unlimited supply of insulin-making cells for transplantation and cure.
  • Developing primary prevention for T1D (e.g., vaccine) and global distribution to eradicate the disease.

TrialNet Studies
Since 1990, BDC investigators and resources have been essential to the NIH-sponsored Diabetes Prevention Program Type 1 (DPT-1), Immune Tolerance Network (ITN) and Type 1 Diabetes TrialNet clinical trial consortia as well as multi-center trials sponsored JDRF and the Helmsley Foundations. This is a shared effort of the Pediatric and Adult Diabetes Divisions of BDC, currently led by Drs. Peter Gottlieb and Andrea Steck.

 For more information:

https://www.trialnet.org/our-research

The BDC has been a driving force in diabetes care in the development of new technology for insulin delivery systems and blood glucose monitoring with the goal of constantly improving the management of type 1 diabetes (T1D)  in children and improving long term outcomes in patients worldwide. Pediatric and Adult Diabetes Divisions of BDC collaborate and share resources in a number of clinical trials, educational programs and translation to clinical care.

  • The BDC will remain on the forefront in the development of new technologies (e.g. artificial pancreas) that are effective, easier to use and eliminate long-term vascular complications while vastly improving quality of life.